For a methicillin-resistant Staphylococcus aureus (MRSA) infection, which agents are appropriate for treatment according to the guidelines?

Prepare for the CAMLPR Microbiology Test. Utilize flashcards and engaging multiple-choice questions, each equipped with descriptions and explanations. Ready yourself for an excellent performance!

Multiple Choice

For a methicillin-resistant Staphylococcus aureus (MRSA) infection, which agents are appropriate for treatment according to the guidelines?

When treating MRSA, you need drugs with proven activity against MRSA, because these strains resist many common beta-lactams. The list that fits guidelines includes vancomycin, linezolid, daptomycin, and ceftaroline. Vancomycin remains a foundational IV option for invasive MRSA infections such as bacteremia, endocarditis, and serious skin/soft-tissue infections. It’s trusted for systemic coverage and is often used when rapid MRSA activity is needed, with trough monitoring to guide dosing. Linezolid, available IV or oral, offers flexible MRSA coverage across several contexts, including skin infections and pneumonia, and is useful when oral therapy or rapid step-down is desired. Be mindful of potential hematologic effects with longer courses and possible drug interactions. Daptomycin is a potent IV agent good for bacteremia and right-sided endocarditis and complicated skin infections. It should not be used for pneumonia, because it is inactivated by pulmonary surfactant, but it’s strong for bloodstream and soft-tissue MRSA infections. Ceftaroline is a fifth-generation cephalosporin with activity against MRSA via PBP2a targeting. It’s approved for complicated skin infections and community-acquired pneumonia, providing another beta-lactam option with MRSA activity. The other listed options, while effective against MSSA or in some susceptible MRSA cases, don’t reliably cover MRSA across all contexts. Penicillins and many cephalosporins lack activity against MRSA, and doxycycline, TMP-SMX, and clindamycin depend on susceptibility and infection type, making them less universally appropriate per guidelines.

When treating MRSA, you need drugs with proven activity against MRSA, because these strains resist many common beta-lactams. The list that fits guidelines includes vancomycin, linezolid, daptomycin, and ceftaroline.

Vancomycin remains a foundational IV option for invasive MRSA infections such as bacteremia, endocarditis, and serious skin/soft-tissue infections. It’s trusted for systemic coverage and is often used when rapid MRSA activity is needed, with trough monitoring to guide dosing.

Linezolid, available IV or oral, offers flexible MRSA coverage across several contexts, including skin infections and pneumonia, and is useful when oral therapy or rapid step-down is desired. Be mindful of potential hematologic effects with longer courses and possible drug interactions.

Daptomycin is a potent IV agent good for bacteremia and right-sided endocarditis and complicated skin infections. It should not be used for pneumonia, because it is inactivated by pulmonary surfactant, but it’s strong for bloodstream and soft-tissue MRSA infections.

Ceftaroline is a fifth-generation cephalosporin with activity against MRSA via PBP2a targeting. It’s approved for complicated skin infections and community-acquired pneumonia, providing another beta-lactam option with MRSA activity.

The other listed options, while effective against MSSA or in some susceptible MRSA cases, don’t reliably cover MRSA across all contexts. Penicillins and many cephalosporins lack activity against MRSA, and doxycycline, TMP-SMX, and clindamycin depend on susceptibility and infection type, making them less universally appropriate per guidelines.

More practice questions